Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, JULY 20, 2026 /PRNEWSWIRE/ -- ATRIUM THERAPEUTICS, INC. (NASDAQ: RNA) (THE "COMPANY") TODAY ANNOUNCED IT AWARDED INDUCEMENT GRANTS ON JULY 20, 2026 UNDER THE COMPANY'S 2026 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (THE "2026 INDUCEMENT PLAN") AS A MATERIAL INDUCEMENT TO THE EMPLOYMENT OF ONE NON-EXECUTIVE INDIVIDUAL NEWLY HIRED BY THE COMPANY. THE EMPLOYEE RECEIVED, IN THE AGGREGATE, NON-QUALIFIED STOCK OPTIONS TO PURCHASE 7,000 SHARES OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.001 PER SHARE, WITH AN EXERCISE PRICE OF $11.76 PER SHARE, THE CLOSING PRICE OF THE COMPANY'S COMMON STOCK AS REPORTED BY NASDAQ ON THE EFFECTIVE DATE OF THE GRANT, 25% OF WHICH WILL VEST AND BECOME EXERCISABLE ON THE FIRST ANNIVERSARY OF THE GRANT DATE, AND THE REMAINING UNDERLYING SHARES WILL VEST IN 36 SUBSTANTIALLY EQUAL INSTALLMENTS EACH MONTH THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE; AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 3,500 SHARES OF THE COMPANY'S COMMON STOCK, 25% OF WHICH WILL VEST IN THE FIRST ANNIVERSARY OF THE GRANT DATE, AND THE REMAINING UNDERLYING SHARES WILL VEST IN 3 SUBSTANTIALLY EQUAL INSTALLMENTS EACH YEAR THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE, OR COLLECTIVELY, THE "AWARDS.

ATRIUM THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN DIEGO, JUNE 23, 2026 /PRNEWSWIRE/ -- ATRIUM THERAPEUTICS, INC. (NASDAQ: RNA) (THE "COMPANY") TODAY ANNOUNCED IT AWARDED INDUCEMENT GRANTS ON JUNE 20, 2026 UNDER THE COMPANY'S 2026 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (THE "2026 INDUCEMENT PLAN") AS A MATERIAL INDUCEMENT TO THE EMPLOYMENT OF EIGHT NON-EXECUTIVE INDIVIDUALS NEWLY HIRED BY THE COMPANY. THE EMPLOYEES RECEIVED, IN THE AGGREGATE, NON-QUALIFIED STOCK OPTIONS TO PURCHASE 66,000 SHARES OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.001 PER SHARE, WITH AN EXERCISE PRICE OF $12.66 PER SHARE, THE CLOSING PRICE OF THE COMPANY'S COMMON STOCK AS REPORTED BY NASDAQ ON THE LAST DATE OF TRADING PRECEDING THE EFFECTIVE DATE OF THE GRANT, 25% OF WHICH WILL VEST AND BECOME EXERCISABLE ON THE FIRST ANNIVERSARY OF THE GRANT DATE, AND THE REMAINING UNDERLYING SHARES WILL VEST IN 36 SUBSTANTIALLY EQUAL INSTALLMENTS EACH MONTH THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE; AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 33,000 SHARES OF THE COMPANY'S COMMON STOCK, 25% OF WHICH WILL VEST IN THE FIRST ANNIVERSARY OF THE GRANT DATE, AND THE REMAINING UNDERLYING SHARES WILL VEST IN THREE SUBSTANTIALLY EQUAL INSTALLMENTS EACH YEAR THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE, OR COLLECTIVELY, THE "AWARDS.

SAN DIEGO, MAY 14, 2026 /PRNEWSWIRE/ -- ATRIUM THERAPEUTICS, INC. (NASDAQ: RNA) ("ATRIUM," "ATRIUM THERAPEUTICS" OR THE "COMPANY"), ABIOPHARMACEUTICAL COMPANYADVANCING PRECISION CARDIOLOGY BY DEVELOPINGRNA THERAPEUTICS TARGETEDTO THE HEART, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND HIGHLIGHTED RECENT CORPORATE PROGRESS FOLLOWING ITS LAUNCH AS A PUBLIC COMPANY. "OUR FOCUSED PIPELINE, STRONG CASH BALANCE AND EXPERIENCED TEAM ARE DRIVING SIGNIFICANT MOMENTUM AS WE BUILD A DEDICATED PRECISION CARDIOLOGY COMPANY," SAID KATHLEEN GALLAGHER, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ATRIUM THERAPEUTICS.

ATRIUM THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SAN DIEGO, APRIL 23, 2026 /PRNEWSWIRE/ --ATRIUM THERAPEUTICS, INC. (NASDAQ: RNA) (THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DELIVERING RNA THERAPEUTICS DIRECTLY TO THE HEART, ANNOUNCED TODAY IT HAS EARNED A $15 MILLION DEVELOPMENT MILESTONE PAYMENT FROM BRISTOL MYERS SQUIBB (NYSE: BMY). THE MILESTONE WAS ACHIEVED UPON THE SUCCESSFUL DELIVERY OF A DEVELOPMENT CANDIDATE FOR THE FIRST LICENSED COMPOUND TARGETING A CARDIOLOGY INDICATION UNDER THE COMPANY'S ONGOING COLLABORATION.

ATRIUM THERAPEUTICS EARNS $15 MILLION MILESTONE PAYMENT FROM BRISTOL MYERS SQUIBB UNDER GLOBAL CARDIOVASCULAR COLLABORATION

SAN DIEGO, APRIL 20, 2026 /PRNEWSWIRE/ --ATRIUM THERAPEUTICS, INC. (NASDAQ: RNA) (THE "COMPANY") TODAY ANNOUNCED IT AWARDED INDUCEMENT GRANTS ON APRIL 20, 2026 UNDER THE COMPANY'S 2026 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (THE "2026 INDUCEMENT PLAN") AS A MATERIAL INDUCEMENT TO THE EMPLOYMENT OF SEVEN NON-EXECUTIVE INDIVIDUALS NEWLY HIRED BY THE COMPANY. THE EMPLOYEES RECEIVED, IN THE AGGREGATE, NON-QUALIFIED STOCK OPTIONS TO PURCHASE 101,250 SHARES OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.001 PER SHARE, WITH AN EXERCISE PRICE OF $14.30 PER SHARE, THE CLOSING PRICE OF THE COMPANY'S COMMON STOCK AS REPORTED BY NASDAQ ON THE EFFECTIVE DATE OF THE GRANT, 25% OF WHICH WILL VEST AND BECOME EXERCISABLE ON THE FIRST ANNIVERSARY OF THE GRANT DATE, AND THE REMAINING UNDERLYING SHARES WILL VEST IN 36 SUBSTANTIALLY EQUAL INSTALLMENTS EACH MONTH THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE; AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 50,625 SHARES OF THE COMPANY'S COMMON STOCK, 25% OF WHICH WILL VEST IN THE FIRST ANNIVERSARY OF THE GRANT DATE, AND THE REMAINING UNDERLYING SHARES WILL VEST IN THREE SUBSTANTIALLY EQUAL INSTALLMENTS EACH YEAR THEREAFTER, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE WITH THE COMPANY THROUGH EACH APPLICABLE VESTING DATE, OR COLLECTIVELY, THE "AWARDS.

SPINOFF FROM NOVARTIS AG'S ACQUISITION OF AVIDITY BIOSCIENCES ADVANCES PRECISION CARDIOLOGY PROGRAMS USING TARGETED RNA DELIVERY PLATFORM LEAD CANDIDATES ATR 1072 AND ATR 1086 EXPECTED TO ENTER CLINICAL TRIALS FOR PRKAG2 SYNDROME AND PLN CARDIOMYOPATHY, RESPECTIVELY SAN DIEGO, FEB. 27, 2026 /PRNEWSWIRE/ -- ATRIUM THERAPEUTICS, INC. (NASDAQ: RNA) LAUNCHED TODAY AS A NEWLY INDEPENDENT, PUBLICLY TRADED COMPANY DEDICATED TO DELIVERING RNA THERAPEUTICS DIRECTLY TO THE HEART TO TRANSFORM CARE FOR PEOPLE LIVING WITH RARE, LIFE-THREATENING GENETIC CARDIOMYOPATHIES. ATRIUM THERAPEUTICS WAS ESTABLISHED IN CONNECTION WITH AVIDITY BIOSCIENCES, INC.'S ACQUISITION BY NOVARTIS AG.

ATRIUM THERAPEUTICS LAUNCHES WITH APPROXIMATELY $270 MILLION TO ADVANCE NOVEL RNA MEDICINES FOR RARE GENETIC CARDIOMYOPATHIES

SAN DIEGO, FEB. 26, 2026 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. ("AVIDITY") (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS) TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT THE COMPANY WILL BE PRESENTING ONE ORAL AND SIX POSTER PRESENTATIONS AT THE 2026 MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL & SCIENTIFIC CONFERENCE, BEING HELD MARCH 8-11, 2026, IN ORLANDO, FLORIDA. 2026 MDA CLINICAL & SCIENTIFIC CONGRESS PRESENTATIONS ORAL PRESENTATION: DEL-ZOTA TREATMENT IS ASSOCIATED WITH NEAR NORMALIZATION OF CK LEVELS AND IMPROVEMENTS IN KEY FUNCTIONAL OUTCOMES AT 1 YEAR IN PARTICIPANTS WITH DMD44 (MARCH 11, 2026: 12:30 P.M.

AVIDITY BIOSCIENCES ANNOUNCES MULTIPLE UPCOMING PRESENTATIONS AT 2026 MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL & SCIENTIFIC CONFERENCE

SAN DIEGO, FEB. 23, 2026 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. ("AVIDITY") (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES ("AOCS") TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT IT INTENDS TO CONVENE ITS UPCOMING SPECIAL MEETING OF STOCKHOLDERS (THE "SPECIAL MEETING") SCHEDULED FOR FEBRUARY 23, 2026, AT 10:00 A.M., EASTERN TIME, AND THEN IMMEDIATELY ADJOURN PROCEEDINGS, WITHOUT CONDUCTING ANY OTHER BUSINESS.

AVIDITY BIOSCIENCES ANNOUNCES INTENTION TO ADJOURN AND RECONVENE SPECIAL MEETING OF STOCKHOLDERS

DEL-DESIRAN EFFECTIVELY DELIVERED SIRNA TO MUSCLE, RESULTING IN APPROXIMATELY 40% MEAN REDUCTION IN DMPK MRNA AND AMELIORATION OF MISSPLICING TREATMENT DEMONSTRATED IMPROVEMENTS IN MULTIPLE MEASURES INCLUDING MYOTONIA, MUSCLE FUNCTION AND STRENGTH, MOBILITY AND PATIENT-REPORTED OUTCOMES DEL-DESIRAN SHOWED ACCEPTABLE SAFETY AND TOLERABILITY WITH MOST ADVERSE EVENTS MILD OR MODERATE SAN DIEGO, FEB. 18, 2026 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ:RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS), TODAY ANNOUNCED THAT THE FINAL RESULTS FROM THE COMPLETED PHASE 1/2 MARINA TRIAL OF DELPACIBART ETEDESIRAN (DEL-DESIRAN) IN PEOPLE LIVING WITH MYOTONIC DYSTROPHY TYPE 1 (DM1) WILL BE PUBLISHED IN THE FEBRUARY 19 ISSUE OF THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM). THE MANUSCRIPT IS TITLED "AN ANTIBODY OLIGONUCLEOTIDE CONJUGATE FOR MYOTONIC DYSTROPHY TYPE 1.

THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES RESULTS FROM PHASE 1/2 MARINA TRIAL OF DELPACIBART ETEDESIRAN (DEL-DESIRAN) FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1

Avidity Biosciences, Inc.

RNA

Price

Financial Reports

No items found.

Press Releases

Avidity Biosciences, Inc.

RNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RNA